Nanyang Biologics Partners with NVIDIA, HPE, Equinix for AI Drug Discovery

Nanyang Biologics (NYB) enters a strategic collaboration with NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to build “VECURA”—an AI-powered drug discovery platform that combines advanced predictive models with a proprietary library of millions of natural compounds. Through this initiative, NYB aims to accelerate the development of next-generation health solutions across pharmaceuticals, dietary supplements, functional foods, and personal care. Designed as an “AI-as-a-Service” platform, VECURA seeks to reduce the therapeutic drug discovery timeline from the traditional 10–12 years to just few hours!

The signing event marked the beginning of the collaboration with world renowned heavyweight company NVIDIA, HPE, and Equinix, to co-develop what will become a world-largest AI-curated compound library, anchored in Singapore.

Fischer Medical Ventures Ltd (FMV) known for its affordable, and accessible medical diagnostic and imaging technologies, by leveraging cutting-edge innovations and AI-powered software solutions in healthcare, is proud to be a strategic and early investor in NYB. As the first company to indigenously manufacture high-quality Magnetic Resonance Imaging (MRI) systems in India and owning a diverse portfolio of breakthrough diagnostic solutions, FMV is moving into preventative healthcare space with NYB.

Traditional drug discovery is often slow, costly, and inefficient, hindering the development of life-saving therapeutics. NYB’s VECURA seeks to transform this landscape by harnessing advanced technologies such as AI, machine learning, and virtual screening. Through curating a vast Natural Compound Library from tropical flora, and integrating cutting-edge metagenomics and metaproteomics analysis, VECURA can uncover the therapeutic potential hidden within diverse plants swiftly, enables rapid identification of promising drug candidates, significantly reducing discovery time and costs while opening new frontiers in personalized medicine and nature-based therapeutics.

Beyond drug discovery, NYB is harnessing its AI-powered discovery platform and vast, biodiverse compound library to build a pipeline of evidence-based nutraceuticals designed to enhance human resilience, restore metabolic balance, and promote long-term vitality. At the forefront of this initiative is CareViva™ NS, a longevity-focused formulation derived from traditional herbs and worked on by more than 26 scientists & professors from the prestigious Nanyang Technological University of Singapore. As NYB’s global distribution partner, FMV will leverage on its extensive network to bring this next generation of nutraceuticals to market, making advanced, science-backed wellness solutions accessible to consumers worldwide.

Mr. Ravindran Govindan, Executive Chairman & MD of FMV, celebrates the strategic collaboration: “We believe that with the strong support of world-class companies like NVIDIA, HPE and Equinix, NYB’s supercharged VECURA platform will unleash powerful therapeutic potential of nature with AI and discover millions of valuable natural compounds in shorter time to enable any Biotech companies to use to develop their health and wellness products faster. We are especially excited to extend NYB’s groundbreaking drug discovery platform to India, the land of Ayurvedic, to work on traditional herbs native to India, and globalize Ayurveda through AI-driven platforms like VECURA”.

FMV stands as the vanguard of a paradigm shift in healthcare, pioneering revolutionary medical imaging technologies and diagnostics on a global scale. With a visionary outlook, FMV aspires to become the premier partner for healthcare providers worldwide, renowned for its production of cost-effective, top-tier medical imaging devices and groundbreaking diagnostic solutions. The Company is the first in India to develop advanced magnetic resonance imaging (MRI) system and also carry a comprehensive spectrum of healthcare products & services tailored to elevate patient care and outcomes. Leveraging on their unparalleled expertise, vast resources, and strategic collaborations, the Company is steadfast to catalyse progress, foster accessibility, and redefine affordability in global healthcare. FMV is listed on the National Stock Exchange (FISCHER) and Bombay Stock Exchange (524743).